• Investors
  • News
  • Careers
  • Contact
  • Global Need
    • Vaccines
    • History & Impact
  • Our Solution
    • Oral Vaccines
    • Technology
    • Vaccine Advantages
    • Platform Advantages
  • Pipeline
    • Research & Development
    • Norovirus
    • Influenza
    • RSV
    • HPV
  • About Us
    • Our Mission
    • Our Team
    • Careers
    • Contact
    • Compliance
  • Investors
  • News
  • Careers
  • Contact

Single

An Adenovirus-Based Vaccine with a Double-Stranded RNA Adjuvant Protects Mice and Ferrets against H5N1 Avian Influenza in Oral Delivery Models

Scallan CD, Tingley DW, Lindbloom JD, Toomey JS, Tucker SN. Clin Vaccine Immunol. Published ahead of print 14 November 2012, doi:10.1128/CVI.00552-12.

Abstract

An oral gene-based avian influenza vaccine would allow rapid development and simplified distribution, but efficacy has previously been difficult to achieve by the oral route. This study assessed protection against avian influenza virus challenge using a chimeric adenovirus vector expressing hemagglutinin and a double-stranded RNA adjuvant. Immunized ferrets and mice were protected upon lethal challenge. Further, ferrets immunized by the peroral route induced cross-clade neutralizing antibodies, and the antibodies were selective against hemagglutinin, not the vector. Similarly, experiments in mice demonstrated selective immune responses against HA with peroral delivery and the ability to circumvent preexisting vector immunity.

Post navigation

Previous PostPrevious
Next PostNext
Media Contacts

Katie Hogan, WCG
415.658.9745
khogan@wcgworld.com

Samir Singh, Vaxart
908.720.622,4
ssignh@vaxart.com

Get Updates

Subscribe to receive news alerts now.

© 2020 Vaxart, Inc., All rights reserved. Terms of UsePrivacy Policy